Fabregas, J. C., Hoffman, J. E., Koru-Sengul, T., Feng, M., Goodman, D., Serafini, A., … Lossos, I. S. (2014). Phase II study of (90)y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma. In BLOOD (Vol. 124). San Francisco, CA: AMER SOC HEMATOLOGY.

Fabregas, Jesus C., James E. Hoffman, Tulay Koru-Sengul, Miao Feng, Deborah Goodman, Aldo Serafini, Peter J. Hosein, Alexandra Stefanovic, Joseph D. Rosenblatt, and Izidore S. Lossos. “Phase II study of (90)y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma.” In BLOOD, Vol. 124. AMER SOC HEMATOLOGY, 2014.

Fabregas JC, Hoffman JE, Koru-Sengul T, Feng M, Goodman D, Serafini A, et al. Phase II study of (90)y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma. In: BLOOD. AMER SOC HEMATOLOGY; 2014.

Fabregas, Jesus C., et al. “Phase II study of (90)y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma.” BLOOD, vol. 124, no. 21, AMER SOC HEMATOLOGY, 2014.

Fabregas JC, Hoffman JE, Koru-Sengul T, Feng M, Goodman D, Serafini A, Hosein PJ, Stefanovic A, Rosenblatt JD, Lossos IS. Phase II study of (90)y Ibritumomab Tiuxetan (Zevalin) in Patients with Previously Untreated Marginal Zone Lymphoma. BLOOD. AMER SOC HEMATOLOGY; 2014.